Direct evidence for the involvement of T suppressor cells in the expression of low-dose paralysis to type III pneumococcal polysaccharide.
Prior treatment (priming) with a subimmunogenic dose of type III pneumococcal polysaccharide results in the development of an antigen-specific state of unresponsiveness termed low-dose paralysis. Such unresponsiveness can be transferred by spleen cells obtained from mice within 5 to 24 hr after priming; the suppressive activity of transferred cells is abolished by treatment with monoclonal anti-Thy-1.2 antibody and complement. These findings show clearly that low-dose paralysis is mediated by T suppressor cells.
D000818:Animals; D000921:Antibody-Producing Cells / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D000939:Epitopes; D005260:Female; D007108:Immune Tolerance; D007111:Immunity, Cellular; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D010243:Paralysis / Q000209:etiology* / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000494:pharmacology*; D013296:Streptococcus pneumoniae / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014301:Trinitrobenzenes / Q000276:immunology
D000939:Epitopes; D011135:Polysaccharides, Bacterial; D014301:Trinitrobenzenes